Natalizumab
Carcinoma, Ovarian Epithelial
Institut du Cancer de Montpellier - Val d'AurelleN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
10 Active assets in the Carcinoma, Ovarian Epithelial cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
LENVATINIB University Medical Center Groningen | Phase 4 | BB |
Catequentinib Lei Li | Phase 3 | BB |
kfa115 Novartis Pharmaceuticals | Phase 1 | CC |
bp1001-a Bio-Path Holdings, Inc. | Phase 1 | CC |
ab-1015 Arsenal Biosciences, Inc. | Phase 1 | CC |
View all 11 →
Same molecule, other indications
Natalizumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →